Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells

BACKGROUND: The treatment of high‐risk B‐cell lymphoma (BCL) remains a challenge, especially in the elderly. METHODS: A total of 83 patients (median age 65 years), who have achieved a complete response after induction therapy, were divided into two groups: R(2) + GM‐CSF regimen (lenalidomide, rituxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Shunrong, Fulati, Wulipan, Shen, Lin, Wu, Min, Huang, Zilan, Qian, Wensi, Chen, Pingping, Hu, Yingwei, Chen, Mingyue, Xu, Yu, Zhang, Hongdi, Ma, Jiexian, Xie, Yanhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315792/
https://www.ncbi.nlm.nih.gov/pubmed/37081754
http://dx.doi.org/10.1002/cam4.5969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315792/
https://www.ncbi.nlm.nih.gov/pubmed/37081754
http://dx.doi.org/10.1002/cam4.5969

Ejemplares similares